April 11, 2022 11:15 AM EDTUpdated 02:15 PM

AACR22: Bristol Myers' Opdivo is yet to reach survival endpoint in early-stage lung cancer. But will it matter?

Max Gelman

Senior Editor

NEW ORLEANS — Fresh off a landmark approval for its blockbuster checkpoint inhibitor Opdivo, Bristol Myers Squibb is touting new data at AACR it hopes will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AACR22: Bristol Myers' Opdivo is yet to reach survival endpoint in early-stage lung cancer. But will it matter?

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech

AACR22: Bris­tol My­er­s' Op­di­vo is yet to reach sur­vival end­point in ear­ly-stage lung can­cer. But will it mat­ter?

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

AACR22: Bristol Myers' Opdivo is yet to reach survival endpoint in early-stage lung cancer. But will it matter?

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Gilead buys experimental HIV vaccines from a small Barcelona biotech